drug
BUMETANIDE
Marketedupdated 3mo agoby Edenbridge Pharmaceuticals LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(1)
Trials studying BUMETANIDE
- phase4Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment
- N/AEU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)
- phase3Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
- phase4Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
- N/ADiuretic/Cool Dialysate Trial
- phase3Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 4, 2040
~14.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- May 14, 2045formulationUS 12558330
- Dec 4, 2040formulationUS 11123319
- Dec 4, 2040method-of-use (U-4279)US 11260038
- Dec 4, 2040formulationUS 12329731
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that